MaxCyte, Inc. (MXCT) stock
MXCTNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 9/3065% below fair value
$1.17−0.01 (-0.85%)
Close on Nov 17, 2026Market cap $120.75MP/E –Yield –
MaxCyte gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
MaxCyte's gross profit for the twelve months ending Jun 30, 2026 was $24.60M, down 13.8% year over year. For fiscal 2025 it was $26.80M, down 15.0% from the year before. The highest annual figure on record is $39.16M in fiscal 2022.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $26.80M | -15.0% |
| FY2024 | Dec 31, 2024 | $31.53M | -13.7% |
| FY2023 | Dec 31, 2023 | $36.55M | -6.7% |
| FY2022 | Dec 31, 2022 | $39.16M | +29.5% |
| FY2021 | Dec 31, 2021 | $30.25M | +29.2% |
| FY2020 | Dec 31, 2020 | $23.40M | +22.4% |
| FY2019 | Dec 31, 2019 | $19.12M | – |
Quarterly gross profit
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $5.60M | -19.9% |
| Q1 FY2026 | Mar 31, 2026 | $8.08M | -9.1% |
| Q4 FY2025 | Dec 31, 2025 | $5.69M | -11.3% |
| Q3 FY2025 | Sep 30, 2025 | $5.23M | -16.1% |
| Q2 FY2025 | Jun 30, 2025 | $6.99M | -21.8% |
| Q1 FY2025 | Mar 31, 2025 | $8.89M | -10.5% |
| Q4 FY2024 | Dec 31, 2024 | $6.41M | -54.5% |
| Q3 FY2024 | Sep 30, 2024 | $6.24M | -13.5% |
| Q2 FY2024 | Jun 30, 2024 | $8.94M | +16.6% |
| Q1 FY2024 | Mar 31, 2024 | $9.94M | +31.2% |
| Q4 FY2023 | Dec 31, 2023 | $14.09M | +29.6% |
| Q3 FY2023 | Sep 30, 2023 | $7.21M | -22.2% |
| Q2 FY2023 | Jun 30, 2023 | $7.67M | -9.7% |
| Q1 FY2023 | Mar 31, 2023 | $7.58M | -28.0% |
| Q4 FY2022 | Dec 31, 2022 | $10.88M | +21.9% |
| Q3 FY2022 | Sep 30, 2022 | $9.27M | +0.9% |
| Q2 FY2022 | Jun 30, 2022 | $8.49M | +34.2% |
| Q1 FY2022 | Mar 31, 2022 | $10.52M | +81.4% |
| Q4 FY2021 | Dec 31, 2021 | $8.93M | +17.3% |
| Q3 FY2021 | Sep 30, 2021 | $9.20M | +52.5% |
| Q2 FY2021 | Jun 30, 2021 | $6.32M | +35.0% |
| Q1 FY2021 | Mar 31, 2021 | $5.80M | – |
| Q4 FY2020 | Dec 31, 2020 | $7.61M | – |
| Q3 FY2020 | Sep 30, 2020 | $6.03M | – |
| Q2 FY2020 | Jun 30, 2020 | $4.68M | – |
See a number that looks wrong?